|
Exhibit 10.49
Confidential Materials omitted and filed
separately with the
Securities and Exchange Commission. Asterisks
denote omissions.
FIRST AMENDMENT TO LICENSE, SUPPLY AND
DISTRIBUTION AGREEMENT
THIS FIRST AMENDMENT TO LICENSE, SUPPLY AND DISTRIBUTION
AGREEMENT is made and entered into as of this 19th day of December,
2005 ("Effective Date") by and between F.Hoffmann-La Roche Ltd.
("FHLR") having a principal office at Grenzacherstrasse 124, Basel,
Switzerland and 454 Life Sciences Corporation ("454") having a
principal office at 20 Commercial Street, Branford, CT 06405,
USA.
RECITALS
WHEREAS, the Parties have entered into a written License, Supply
and Distribution Agreement dated May 11, 2005 ("Original
Agreement"); and
WHEREAS, according to the last paragraph of
Section 2.7 of the Original Agreement the Parties wish to
change the Initial estimated ASP in Section 3.3
(b) and Exhibit 2 of the Original Agreement and the Licensed
Products Specifications in Exhibit 3 of the Original Agreement.
NOW THEREFORE, in consideration of the covenants and
mutual promises set forth herein, the receipt and sufficiency of
which are hereby acknowledged, the Parties agree as follows:
1. According to Section 3.3 (b) of the Original
Agreement the Parties hereby define in detail the Licensed
Products, the initial estimated ASP for the Licensed
Products and the launch date by amending Exhibit 2. Exhibit 2 shall
be replaced by the following new Exhibit 2:
(See attached document.)
Furthermore, the launch date for all Licensed Products shall be
September 30, 2005.
2. Exhibit 3 of the Original Agreement shall be deleted
in its entirety and replaced by the following new Exhibit 3:
(See attached document.)
3. The Parties agree that the "Accessories" listed on the
new Exhibit 2 shall be treated the same as the Instrument regarding
the payment of royalties.
4. According to Section 3.3 (c) the Parties
have to agree on the applicable estimated ASP for the
following calendar year latest by November 30 th . In deviation from this
Section 3.3 (c) the Parties agree that for the calendar
year 2006 the applicable estimated ASP shall be as set out
in Section 1 of this First Amendment.
IN WITNESS WHEREOF, each of the Parties has caused this
First Amendment to the Original Agreement to be executed by its
duly authorized representative.
| |
|
|
|
|
|
|
|
|
|
Basel,
F. Hoffmann-La Roche Ltd
|
|
|
|
Branford,
454 Life Sciences
|
|
|
|
|
|
|
By:
|
|
/s/ Severin Schwan
|
|
|
|
By:
|
|
/s/ Christopher K. McLeod
|
|
Name:
|
|
Severin Schwan
|
|
|
|
Name:
|
|
Christopher K. McLeod
|
|
Title:
|
|
CEO Division Diagnostics
|
|
|
|
Title:
|
|
President & CEO
|
|
Date:
|
|
Feb. 6, 2006
|
|
|
|
Date:
|
|
Jan. 9, 2006
|
|
|
|
|
|
By:
|
|
/s/ C. J. Ruetsch
|
|
|
|
|
|
Name:
|
|
C. J. Ruetsch
|
|
|
|
|
|
|
|
Title:
|
|
Legal Counsel
|
|
|
|
|
|
|
|
Date:
|
|
Feb. 2, 2006
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Reagents
|
|
|
|
|
|
|
|
|
Cat. No.
|
|
Product
|
|
ASP
$/Kit
|
|
Transfer Price
$/Sub Kit
|
|
|
|
04746694001
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
|
|
|
|
04746708001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746716001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746724001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746732001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746503001
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
|
|
|
|
04746511001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746520001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746538001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746546001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746554001
|
|
|
|
[**]
|
|
[**]
|
|
|
|
|
|
|
|
|
04746562001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746589001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746597001
|
|
|
|
|
|
[**]
|
|
|
|
|
|
|
|
|
04746619001
|
|
|
|
|
|
[**]
|
|
|
|
|
|